WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018045450) BISPHENOL A COMPOUNDS AND METHODS FOR TREATING DRUG-RESISTANT ANDROGEN RECEPTOR MEDIATED CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/045450    International Application No.:    PCT/CA2017/000201
Publication Date: 15.03.2018 International Filing Date: 08.09.2017
IPC:
A61K 31/09 (2006.01), A61P 35/00 (2006.01), C07C 43/23 (2006.01)
Applicants: BRITISH COLUMBIA CANCER AGENCY BRANCH [CA/CA]; 600 West 10th Avenue Vancouver, British Columbia V5Z 4E6 (CA).
THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; University-Industry Liaison Office #103-6190 Agronomy Road Vancouver, British Columbia V6T 1ZE (CA)
Inventors: SADAR, Marianne Dorothy; (CA).
MAWJI, Nasrin R.; (CA).
OBST, Jonathon Kyle; (CA).
ANDERSEN, Raymond John; (CA).
WILLIAMS, David E.; (CA).
JIAN, Kunzhong; (CA)
Agent: DEETH WILLIAMS WALL LLP; 150 York Street, Suite 400 Toronto, Ontario M5H 3S5 (CA)
Priority Data:
62/385,648 09.09.2016 US
Title (EN) BISPHENOL A COMPOUNDS AND METHODS FOR TREATING DRUG-RESISTANT ANDROGEN RECEPTOR MEDIATED CANCERS
(FR) COMPOSÉS DE BISPHÉNOL A, ET MÉTHODES DE TRAITEMENT DE CANCERS POSITIFS POUR LE RÉCEPTEUR AUX ANDROGÈNES RÉSISTANTS AUX MÉDICAMENTS
Abstract: front page image
(EN)The present invention provides methods for treating cancer comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein the cancer, cancer cells, or tumour cells are resistant to a cancer agent which is susceptible to glucuronidation. R1, R2, R3, R11a, R11b, R11c, and R11d are as defined herein. (Formula (I))
(FR)La présente invention concerne des méthodes de traitement du cancer, comprenant un composé de formule (I) ou un sel, tautomère ou stéréoisomère pharmaceutiquement acceptable correspondant, le cancer, les cellules cancéreuses ou les cellules tumorales étant résistants à un agent anticancéreux qui est susceptible de subir une glucuronidation. R1, R2, R3, R11a, R11b, R11c, et R11d sont tels que définis dans la description. (Formule (I))
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)